Using the cutoff point of CPS ≥1, 26% (n=21) of the total number of patients with ES-SCLC (i.e., n=80) had tumors that were positive for both PD-L1 and PD-L2 (double positive) and 59% (n=47) were negative for both PD-L1 and PD-L2 (double negative). This evidence concerns the gene CD274 and small cell lung carcinoma.